Helping people breathe easy and sleep properly are the core of Sunovion. The company focuses its drug development efforts in two main therapeutic categories: respiratory and central nervous system (CNS) disorders. Among its marketed products are asthma drug Xopenex, insomnia therapy Lunesta, schizophrenia treatment Latuda, and chronic obstructive pulmonary disease (COPD) treatment Brovana. Sunovion markets its products to primary care physicians and some specialists in the US. Sunovion is a subsidiary of Japanese firm Dainippon Sumitomo Pharma (DSP).